Light4Lungs departs from current paradigms as bacterial infections will be treated by a breathable light source, thus:
(1) Without including any externally added drug it overcomes the multidrug resistance profile;
(2) With eliciting the therapeutic action by a breathable light source it avoids the use of invasive physical tethers.
The encompasses the development of particles with persistent luminescence, the aerosol technology for activation and delivery to the lungs, and the definition of the treatment parameters through toxicity and efficacy tests in clinically relevant models of respiratory infections. Its results have the potential to go beyond treatment of recalcitrant respiratory tract bacterial infections to other lung diseases and to other organs, enriching fields of healthcare, nanomedicine, materials science and nanotechnology.
The Consortium, with 8 partners from 4 countries, is highly interdisciplinary and synergetic, combining several different scientific areas from photonics to medicine, including materials chemistry, physical chemistry, photo-physics, pharmaceutics, photobiology and microbiology. Multidisciplinary teams will be assemble to ensure cross-talk between disciplines and specialists throughout the project.
Facts in brief
As is customary one year in, the Light4Lungs project was reviewed on 27 January. This was an opportunity to take a look at the progress made over the previous twelve months and check that the project is on track to meet its milestones. The EU-funded Light4Lungs...
The Light4Lungs team has issued a newsletter with an update on all the latest project developments. Our consortium is formed of eight partners located in four different European countries combining a broad range of specialised scientific areas, including photonics,...